Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Kodiak Sciences Inc.
13D/A
KOD · 50015M109
|
35.0% |
9/30/2026
Event 9/28/2026
|
|||
| Baker Bros. Advisors LP | 35.0% | ||||
| Baker Bros. Advisors (GP) LLC | 35.0% | ||||
| Julian C. Baker | 35.0% | ||||
| Felix J. Baker | 35.0% | ||||
|
BeOne Medicines Ltd.
13D/A
ONC · 07725L102
|
7.8% |
9/16/2026
Event 9/14/2026
|
|||
| Baker Bros. Advisors LP | 7.8% | ||||
| Baker Bros. Advisors (GP) LLC | 7.8% | ||||
| Julian C. Baker | 7.8% | ||||
| Felix J. Baker | 7.8% | ||||
| FBB3 LLC | <0.1% | ||||
|
IDEAYA Biosciences, Inc.
13G
IDYA · 45166A102
|
5.2% |
8/14/2026
Event 6/30/2026
|
|||
| Baker Bros. Advisors LP | 5.2% | ||||
| Baker Bros. Advisors (GP) LLC | 5.2% | ||||
| Julian C. Baker | 5.2% | ||||
| Felix J. Baker | 5.2% | ||||
|
Revolution Medicines, Inc.
13G
RVMD · 76155X100
|
5.3% |
8/14/2026
Event 6/30/2026
|
|||
| Baker Bros. Advisors LP | 5.3% | ||||
| Baker Bros. Advisors (GP) LLC | 5.3% | ||||
| Julian C. Baker | 5.3% | ||||
| Felix J. Baker | 5.3% | ||||
|
Immatics N.V.
13G/A
IMTX · N44445109
|
7.0% |
8/14/2026
Event 6/30/2026
|
|||
| Baker Bros. Advisors LP | 7.0% | ||||
| Baker Bros. Advisors (GP) LLC | 7.0% | ||||
| Julian C. Baker | 7.0% | ||||
| Felix J. Baker | 7.0% | ||||
|
Edgewise Therapeutics, Inc.
13G/A
EWTX · 28036F105
|
3.4% |
8/14/2026
Event 6/30/2026
|
|||
| Baker Bros. Advisors LP | 3.4% | ||||
| Baker Bros. Advisors (GP) LLC | 3.4% | ||||
| Julian C. Baker | 3.4% | ||||
| Felix J. Baker | 3.4% | ||||
|
Cerus Corporation
13G/A
CERS · 157085101
|
3.2% |
8/14/2026
Event 6/30/2026
|
|||
| Baker Bros. Advisors LP | 3.2% | ||||
| Baker Bros. Advisors (GP) LLC | 3.2% | ||||
| Julian C. Baker | 3.2% | ||||
| Felix J. Baker | 3.2% | ||||
|
Replimune Group, Inc.
13D/A
REPL · 76029N106
|
11.8% |
8/11/2026
Event 8/9/2026
|
|||
| Baker Bros. Advisors LP | 11.8% | ||||
| Baker Bros. Advisors (GP) LLC | 11.8% | ||||
| Julian C. Baker | 11.8% | ||||
| Felix J. Baker | 11.8% | ||||
|
Celcuity Inc.
13G
CELC · 15102K100
|
10.0% |
7/16/2026
Event 7/14/2026
|
|||
| Baker Bros. Advisors LP | 10.0% | ||||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||||
| Julian C. Baker | 10.0% | ||||
| Felix J. Baker | 10.0% | ||||
|
Kiniksa Pharmaceuticals International, plc
13D/A
KNSA · G52694109
|
7.0% |
5/26/2026
Event 5/21/2026
|
|||
| Baker Bros. Advisors LP | 6.9% | ||||
| Baker Bros. Advisors (GP) LLC | 6.9% | ||||
| Julian C. Baker | 7.0% | ||||
| Felix J. Baker | 7.0% | ||||
| FBB3 LLC | <0.1% | ||||
|
Monte Rosa Therapeutics, Inc.
13G/A
GLUE · 61225M102
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Baker Bros. Advisors LP | 10.0% | ||||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||||
| Julian C. Baker | 10.0% | ||||
| Felix J. Baker | 10.0% | ||||
|
GRAIL, Inc.
13G/A
GRAL · 384747101
|
9.8% |
5/15/2026
Event 3/31/2026
|
|||
| Baker Bros. Advisors LP | 9.8% | ||||
| Baker Bros. Advisors (GP) LLC | 9.8% | ||||
| Julian C. Baker | 9.8% | ||||
| Felix J. Baker | 9.8% | ||||
|
KALA BIO, Inc.
13G/A
KALA · 483119301
|
<0.1% |
5/15/2026
Event 3/31/2026
|
|||
| Baker Bros. Advisors LP | <0.1% | ||||
| Baker Bros. Advisors (GP) LLC | <0.1% | ||||
| Julian C. Baker | <0.1% | ||||
| Felix J. Baker | <0.1% | ||||
|
Praxis Precision Medicines, Inc.
13G
PRAX · 74006W207
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Baker Bros. Advisors LP | 6.3% | ||||
| Baker Bros. Advisors (GP) LLC | 6.3% | ||||
| Julian C. Baker | 6.3% | ||||
| Felix J. Baker | 6.3% | ||||
|
Incyte Corp
13D/A
INCY · 45337C102
|
15.6% |
5/11/2026
Event 5/7/2026
|
|||
| Baker Bros. Advisors LP | 15.4% | ||||
| Baker Bros. Advisors (GP) LLC | 15.4% | ||||
| Julian C. Baker | 15.6% | ||||
| Felix J. Baker | 15.6% | ||||
| FBB2, LLC | <0.1% | ||||
| FBB3 LLC | <0.1% | ||||
| FBB Associates | <0.1% | ||||
|
AbCellera Biologics Inc.
13G/A
ABCL · 00288U106
|
10.8% |
5/7/2026
Event 4/30/2026
|
|||
| Baker Bros. Advisors LP | 10.8% | ||||
| Baker Bros. Advisors (GP) LLC | 10.8% | ||||
| Julian C. Baker | 10.8% | ||||
| Felix J. Baker | 10.8% | ||||
|
Prelude Therapeutics Inc
13D/A
PRLD · 74065P101
|
15.5% |
4/22/2026
Event 4/20/2026
|
|||
| Baker Bros. Advisors LP | 15.5% | ||||
| Baker Bros. Advisors (GP) LLC | 15.5% | ||||
| Julian C. Baker | 15.5% | ||||
| Felix J. Baker | 15.5% | ||||
|
ACADIA Pharmaceuticals Inc.
13D/A
ACAD · 004225108
|
25.4% |
2/26/2026
Event 2/24/2026
|
|||
| Baker Bros. Advisors LP | 25.3% | ||||
| Baker Bros. Advisors (GP) LLC | 25.3% | ||||
| Julian C. Baker | 25.4% | ||||
| Felix J. Baker | 25.4% | ||||
| FBB3 LLC | <0.1% | ||||
|
Alkermes plc.
13G
ALKS · G01767105
|
6.1% |
2/17/2026
Event 12/31/2025
|
|||
| Baker Bros. Advisors LP | 6.1% | ||||
| Baker Bros. Advisors (GP) LLC | 6.1% | ||||
| Julian C. Baker | 6.1% | ||||
| Felix J. Baker | 6.1% | ||||
|
KALA BIO, Inc.
13G/A
KALA · 483119202
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Baker Bros. Advisors LP | 10.0% | ||||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||||
| Julian C. Baker | 10.0% | ||||
| Felix J. Baker | 10.0% | ||||
|
Nurix Therapeutics, Inc.
13G/A
NRIX · 67080M103
|
7.2% |
2/17/2026
Event 12/31/2025
|
|||
| Baker Bros. Advisors LP | 7.2% | ||||
| Baker Bros. Advisors (GP) LLC | 7.2% | ||||
| Julian C. Baker | 7.2% | ||||
| Felix J. Baker | 7.2% | ||||
|
Stoke Therapeutics, Inc.
13G/A
STOK · 86150R107
|
5.8% |
2/17/2026
Event 12/31/2025
|
|||
| Baker Bros. Advisors LP | 5.8% | ||||
| Baker Bros. Advisors (GP) LLC | 5.8% | ||||
| Julian C. Baker | 5.8% | ||||
| Felix J. Baker | 5.8% | ||||
|
DBV Technologies S.A.
13D/A
DBVT · 23306J309
|
10.0% |
1/14/2026
Event 1/12/2026
|
|||
| Baker Bros. Advisors LP | 10.0% | ||||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||||
| Julian C. Baker | 10.0% | ||||
| Felix J. Baker | 10.0% | ||||
|
Kymera Therapeutics, Inc.
13D/A
KYMR · 501575104
|
10.9% |
12/11/2025
Event 12/9/2025
|
|||
| Baker Bros. Advisors LP | 10.9% | ||||
| Baker Bros. Advisors (GP) LLC | 10.9% | ||||
| Julian C. Baker | 10.9% | ||||
| Felix J. Baker | 10.9% | ||||
|
IGM Biosciences, Inc.
13D/A
IGMS · 449585108
|
0% |
8/18/2025
Event 8/14/2025
|
|||
| Baker Bros. Advisors LP | 0% | ||||
| Baker Bros. Advisors (GP) LLC | 0% | ||||
| Julian C. Baker | 0% | ||||
| Felix J. Baker | 0% | ||||
|
Neurogene Inc.
13G/A
NGNE · 64135M105
|
7.0% |
8/14/2025
Event 6/30/2025
|
|||
| Baker Bros. Advisors LP | 7.0% | ||||
| Baker Bros. Advisors (GP) LLC | 7.0% | ||||
| Julian C. Baker | 7.0% | ||||
| Felix J. Baker | 7.0% | ||||
|
Candel Therapeutics, Inc.
13G/A
CADL · 137404109
|
4.99% |
5/15/2025
Event 3/31/2025
|
|||
| Baker Bros. Advisors LP | 4.99% | ||||
| Baker Bros. Advisors (GP) LLC | 4.99% | ||||
| Julian C. Baker | 4.99% | ||||
| Felix J. Baker | 4.99% | ||||
|
Rhythm Pharmaceuticals, Inc.
13G/A
RYTM · 76243J105
|
8.9% |
5/15/2025
Event 3/31/2025
|
|||
| Baker Bros. Advisors LP | 8.9% | ||||
| Baker Bros. Advisors (GP) LLC | 8.9% | ||||
| Julian C. Baker | 8.9% | ||||
| Felix J. Baker | 8.9% | ||||
|
Sera Prognostics, Inc.
13D
SERA · 81749D107
|
16.1% |
2/14/2025
Event 2/12/2025
|
|||
| Baker Bros. Advisors LP | 16.1% | ||||
| Baker Bros. Advisors (GP) LLC | 16.1% | ||||
| Julian C. Baker | 16.1% | ||||
| Felix J. Baker | 16.1% | ||||
|
Biomea Fusion, Inc.
13G/A
BMEA · 09077A106
|
4.0% |
2/14/2025
Event 12/31/2024
|
|||
| Baker Bros. Advisors LP | 4.0% | ||||
| Baker Bros. Advisors (GP) LLC | 4.0% | ||||
| Julian C. Baker | 4.0% | ||||
| Felix J. Baker | 4.0% | ||||